San Francisco, CA - The CDCN is excited for two major upcoming meetings!

Physicians/Researchers: The third annual "Accelerating Research & Treatments for Castleman disease" working dinner meeting will occur on December 6, 2014 at 6:00-9:00pm at the American Society of Hematology Annual Meeting. It will bring together physicians and researchers from around the world for the third time to discuss recent Castleman disease (CD) breakthroughs, determine priorities for the field, and continue to execute on our plan for curing CD! For more information and to register, go to 

This with be the fourth national/international meeting in four months for CDCN co-founders, Drs. David Fajgenbaum and Frits van Rhee. In September, they proposed a new sub classification system to the Centers for Medicare/Medicaid Services in Baltimore, MD. In October, they spoke at an MCD symposium during the American Society of Clinical Pathology (ASCP) annual meeting along with world-famous hematopathologist, Dr. Ahmet Dogan, from Memorial Sloan-Kettering Cancer Center. In November, they will present at HEMO, the Brazilian Congress of Hematology's, annual meeting in Florionopolis, Brazil. 

Patients/Loved ones:  The CDCN, CARE, and International Castleman’s Disease Organization (ICDO) is pleased to be holding the first "Beating Castleman's, Together" Patients & Loved Ones Summit in San Francisco! The Summit will coincide with the 2014 American Society of Hematology (ASH) meeting, so that physicians will be able to attend as well.

Many of our patients and loved ones have connected with one another in our Facebook groups and on the Castleman disease patient forum—now is the time to meet each other in person and to learn more about your disease, current research, and ways to join the fight to advance research and treatments! We are hoping to be able to provide financial assistance to those patients with significant financial need, who would not be able to attend otherwise. 
Click here for more information and to register for the Summit.


There are no comments yet.

Leave a Comment